Alternatives to Aggressive Therapy in Mantle Cell Lymphoma
Peter Martin, M.D., assistant professor of Medicine in the Division of Hematology/Oncology, talks to Targeted Oncology about the evolving paradigm of treatment for mantle cell lymphoma. Martin says the evolution of the paradigm currently includes Bruton's tyrosine kinase inhibitor, phosphoinositide 3-kinase inhibitor, immunomodulatory treatments, and immunotherapies.
Martin says all the drugs mentioned have shown varying degrees of activity in mantle cell lymphoma, especially in the frontline setting. For patients with mantle cell lymphoma who are not amenable to particularly aggressive therapies, these treatments may provide alternative options.